Overview

• The FDA granted approval on June 17 for a prefilled syringe presentation of Shingrix, removing the need for healthcare providers to mix separate antigen and adjuvant vials.
• The vaccine’s core components — the glycoprotein E antigen and AS01B adjuvant system — remain unchanged in the new format.
• Since its US launch in 2017, more than 90 million doses of Shingrix have been administered to adults 50 and older and to immunocompromised adults aged 18 and above.
• Shingrix is indicated for adults aged 50 years or older and for those 18 and older at increased risk due to immunodeficiency or immunosuppression.
• Shingles affects about one million Americans each year, with postherpetic neuralgia emerging as the most common severe complication.